{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:41:08Z","timestamp":1775241668758,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,2,26]],"date-time":"2007-02-26T00:00:00Z","timestamp":1172448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> Large\u2010scale studies of rabeprazole\u2010based <jats:italic>Helicobacter pylori<\/jats:italic> eradication therapy have not been reported in Japan.<\/jats:p><jats:p><jats:bold>Aims<\/jats:bold> To evaluate <jats:italic>H. pylori<\/jats:italic> eradication by rabeprazole\u2010based therapy with reference to antibiotic susceptibility, CYP2C19 genotype, and rabeprazole and clarithromycin dosages.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> From 35 centres 479 <jats:italic>H. pylori<\/jats:italic>\u2010positive patients with gastric or duodenal ulcer were randomized to four treatment groups: Group 1 (10\u2003mg rabeprazole\u2003+\u2003750\u2003mg amoxicillin\u2003+\u2003200\u2003mg clarithromycin twice daily for 7\u2003days); Group 2 (10\u2003mg, 750\u2003mg, 400\u2003mg); Group 3 (20\u2003mg, 750\u2003mg, 200\u2003mg) and Group 4 (20\u2003mg, 750\u2003mg, 400\u2003mg).<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> Eradication rates were 86% (102 of 119), 89% (97 of 109), 91% (106 of 116) and 90% (104 of 115) for Groups 1\u20134, respectively. The eradication rate was 95% (360 of 379) for clarithromycin\u2010susceptible strains, and 50% (30 of 60) for clarithromycin\u2010resistant strains. The eradication rates were 88% (332 of 379) and 96% (77 of 80) in extensive metabolizers and poor metabolizers, respectively.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> Rabeprazole\u2010based therapies achieved 50% eradication of clarithromycin\u2010resistant <jats:italic>H. pylori<\/jats:italic>, and even achieved good rates in extensive metabolizers. Accordingly, rabeprazole can be recommended as part of a first\u2010line proton pump inhibitor\u2010based triple therapy for <jats:italic>H. pylori<\/jats:italic>.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03298.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T11:25:21Z","timestamp":1279884321000},"page":"1105-1113","source":"Crossref","is-referenced-by-count":49,"title":["Rabeprazole\u2010based eradication therapy for <i>Helicobacter pylori<\/i>: a large\u2010scale study in Japan"],"prefix":"10.1111","volume":"25","author":[{"given":"H.","family":"KUWAYAMA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"ASAKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"SUGIYAMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"FUKUDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"AOYAMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"HIRAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"FUJIOKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"THE JAPAN RABEPRAZOLE STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,26]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01169.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2001.00027.x"},{"issue":"11","key":"e_1_2_7_4_2","first-page":"198","article-title":"Drug resistant H. pylori in Japan: general remarks","volume":"63","author":"Murakami K","year":"2005","journal-title":"Nippon Rinsho"},{"issue":"3","key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","article-title":"Review article: Cytochrome P450 and the metabolism of proton pump inhibitors \u2013 emphasis of rabeprazole","volume":"13","author":"Ishizaki T","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113959"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90214-3"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01496.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01348.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00840.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02347561"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2001.00018.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00009968"},{"key":"e_1_2_7_14_2","volume-title":"Performance standards for antimicrobial susceptibility testing; ninth informational supplement","author":"National Committee for Clinical Laboratory Standards","year":"1999"},{"key":"e_1_2_7_15_2","first-page":"561","article-title":"A report of the amoxicillin and clarithromycin breakpoints of MIC in H. pylori eradication therapy","volume":"48","author":"Nasu M","year":"2000","journal-title":"Jpn J Chemother"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02029.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01492.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(01)80043-8"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200301000-00006"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01063.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01406.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.10.003"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.1.8"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.6.1025"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2006.06.002"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/00313020120105624"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-1-200201010-00008"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200525050-00002"},{"key":"e_1_2_7_29_2","first-page":"10","article-title":"Relationship between eradication therapy and clarithromycin\u2010resistant Helicobacter pylori in Japan","volume":"35","author":"Hoshiya S","year":"2000","journal-title":"J Gastroenterol"},{"issue":"2","key":"e_1_2_7_30_2","first-page":"460","article-title":"Eradication therapy for clarithromycin\u2010resistant and metronidazole\u2010resistant Helicobacter pylori infection","volume":"60","author":"Inoue K","year":"2002","journal-title":"Nippon Rinsho"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02116532"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03298.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03298.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:23:56Z","timestamp":1697232236000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03298.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,26]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03298.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03298.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,26]]}}}